Activation of peroxisome proliferator-activated receptor-β/δ attenuates myocardial ischemia/reperfusion injury in the rat

Shock

Volumn 34, Issue 2, 2010, Pages 117-124

  Kapoor, Amar ^b   Collino, Massimo ^b   Castiglia, Sara ^b   Fantozzi, Roberto ^b   Thiemermann, Christoph ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

Akt; GSK 3 ; I R injury; NF B; PPAR

Indexed keywords

CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; GLYCOGEN SYNTHASE KINASE 3BETA; GW 6471; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NOS2 PROTEIN, RAT; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PTGS2 PROTEIN, RAT; THIAZOLE DERIVATIVE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; HEART MUSCLE; HEMODYNAMICS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PHOSPHORYLATION; WISTAR RAT;

ANIMALS; CYCLOOXYGENASE 2; GLYCOGEN SYNTHASE KINASE 3; HEMODYNAMICS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; OXAZOLES; PHOSPHORYLATION; PPAR ALPHA; PPAR DELTA; PPAR-BETA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; THIAZOLES; TYROSINE;

EID: 77954998986     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181cd86d6     Document Type: Article

References (35)

1. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988.
2. Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W: Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol Cell 77:67-76, 1993.
3. Das SK, Chakrabarti R: Role of PPAR in cardiovascular diseases. Recent Patents Cardiovasc Drug Discov 1:193-209, 2006.
4. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, et al.: Activation of peroxisome proliferator- activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108:2393-2399, 2003.
5. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16:1027-1040, 2002. (Pubitemid 34753509)
6. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, et al.: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245-1250, 2004.
7. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M: Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518-524, 2003.
8. Reilly SM, Lee CH: PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 582:26-31, 2008.
9. Sheng L, Ye P, Liu YX, Han CG, Zhang ZY: Peroxisome proliferator- activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin Exp Hypertens 30:109-119, 2008.
10. Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, et al.: PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci USA 105:4277-4282, 2008.
11. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN: In vivo activation of peroxisome proliferator- activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther 325:466-474, 2008.
12. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L: The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 181:29-37, 2005.
13. Baller D, Zipfel J, Hellige G: Usefulness and limitations of myocardial oxygen consumption indices. Clin Cardiol 3:212-213, 1980. (Pubitemid 10080253)
14. Nachlas MM, Shnitka TK: Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol 42:379-405, 1963.
15. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, et al.: Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)V synthesis and biological activity. Bioorg Med Chem Lett 13:1517-1521, 2003.
16. Wayman NS, Ellis BL, Thiemermann C: Ligands of the peroxisome proliferatorY activated receptor-PPAR-a reduce myocardial infarct size. Med Sci Monit 8: BR243-BR247, 2002.
17. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296:1655-1657, 2002.
18. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A: Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 104:330-335, 2001.
19. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, Heudes D, Wahli W, Desvergne B, Baud L: Peroxisome proliferatorYactivated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16:2395-2402, 2005.
20. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B: Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10:721-733, 2002.
21. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789, 1995.
22. Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM: Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and-insensitive mechanisms. J Biol Chem 272:7713-7719, 1997.
23. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z: N6-(3-iodobenzyl)-adenosine- 5¶-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mito-chondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J Pharmacol Exp Ther 318:124-131, 2006.
24. Hausenloy DJ, Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448-460, 2004.
25. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K: Erythropoietin affords additional car-dioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 291:H748-H755, 2006.
26. Kovacs K, Toth A, Deres P, Kalai T, Hideg K, Gallyas F Jr, Sumegi B: Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemia-reperfusion. Biochem Pharmacol 71:441-452, 2006.
27. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86-90, 2000.
28. Schwabe RF, Brenner DA: Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 283:G204-G211, 2002.
29. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB: Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279:39541-39554, 2004.
30. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C: GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33:1903-1912, 2005.
31. Gao HK, Yin Z, Zhou N, Feng XY, Gao F, Wang HC: Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 52: 286-292, 2008.
32. Senftleben U, Karin M: The IKK/NF-kappa B pathway. Crit Care Med 30: 18-26, 2002.
33. Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, et al.: Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 57:2149-2157, 2008.
34. Ding G, Cheng L, Qin Q, Frontin S, Yang Q: PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40:821-828, 2006.
35. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M: Peroxisome proliferatorYactivated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65:832-841, 2005.